Wire · opportunities
The peptide gray market is already here. The FDA is just catching up.
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 July 2026 · Fusion42 review
The FDA's Pharmacy Compounding Advisory Committee voted to recommend six peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax) for the 503A bulks list, potentially allowing compounding pharmacies to legally produce them. The vote reflects a shift toward regulated supply amid a booming gray market where Americans currently source peptides from China, with imports doubling to $328 million in 2025.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 23 Jul 2026 and 28 Jul 2026.
◆ ◆ The Wire takeaway
Compounding pharmacies are about to become legal suppliers of peptides that wellness founders have been sourcing from China. This vote kills the gray market advantage—you need to move supply and quality control upstream before the FDA finalizes the rules, probably within months.
◆ Coverage
9 sources · first reported 23 Jul 2026 · latest 28 Jul 2026
◆ Related on Wire
◆ Topics